Dr. Paul LoGerfo, a surgeon who helped advance the diagnosis and treatment of thyroid disease, died on Sept. 16 at Columbia-Presbyterian Medical CeNew YorkNew York.
He also collaborated at Berkeley with physicist Jack Livingood to isolate a number of radioactive isotopes, including iodine-131, which later saved his mother's life and is now used for the diagnosis and treatment of thyroid disorders.
The evaluation and treatment of thyroid lesions in the 5 Japanese CNC patients are summarized in Table 5.
In 1948, Means published a review article on the use of radioiodine in the diagnosis and treatment of thyroid disease [11].
This extraordinary hypothesis may have been built upon the earlier work by Means regarding the potential treatment of thyroid disease using external X-rays [3].
It concludes with a case study of a feasibility study for a KBS to guide surgeons in diagnosis and treatment of thyroid conditions.
The most accepted mean absorbed dose limit to the bone marrow for PRRT is 2 Gy [1, 10], which was originally set based on experiences with 131I therapy for the treatment of thyroid cancer [11 13].
Thus, non-invasive PET imaging of hNIS activity could be used to facilitate the treatment of thyroid and breast cancer and gene therapies that employ hNIS as a reporter gene.
During the luncheon, Saul Hertz who was in attendance spontaneously asked the very pertinent question that perhaps changed the course of treatment of thyroid disease, "Could iodine be made radioactive artificially?" Saul Hertz was born in 1905 in Cleveland, Ohio.
Early in his career, he was a pioneer in nuclear medicine and discovered isotopes of elements with important applications in the diagnosis and treatment of diseases, most notably iodine-131, which is used in the treatment of thyroid disease.
Thus, EGFR intervention alone seems to be insufficient in the treatment of thyroid cancer.
